Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ce |
RCV002070107 | SCV002497996 | likely pathogenic | not provided | 2022-03-01 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002538388 | SCV003712642 | pathogenic | Inborn genetic diseases | 2021-10-19 | criteria provided, single submitter | clinical testing | The c.2252G>A (p.C751Y) alteration is located in exon 17 (coding exon 17) of the AGO2 gene. This alteration results from a G to A substitution at nucleotide position 2252, causing the cysteine (C) at amino acid position 751 to be replaced by a tyrosine (Y). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration has been reported de novo in monozygotic twins and another unrelated patient with neurodevelopmental disorders, including varying degrees of intellectual disability, delayed motor development, impaired speech and receptive language development, and other variable features (Lessel, 2020). This amino acid position is highly conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek, 2016; Firth, 2009). The p.C751 amino acid is located at the base of a loop in the PIWI domain that binds to the minor groove in the guide/target duplex and regulates the interaction between RNA and the MID domain. Functional studies showed that this alteration significantly reduces shRNA-mediated silencing of Shank3 but not δ-catenin, suggesting target mRNA specific effects of the alteration (Lessel, 2020). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. |
| OMIM | RCV001289986 | SCV001478019 | pathogenic | Lessel-Kreienkamp syndrome | 2021-01-20 | no assertion criteria provided | literature only |